Dr. Octavian Florescu, PhD, has over 10 years of experience in the semiconductor/IT space working with DEC, GE, Nokia, Quake Technologies and Qualcomm, where he developed control systems for nuclear reactors, software for network management, high speed digital blocks for 10Gb/s and 40Gb/s Ethernet, baseband PLLs for digital timing and RF front-ends for cellular communication. He received his B.S. in Computer Engineering from the University of Waterloo, Canada in 2004, and his PhD in Electrical Engineering from UC Berkeley, with a minor in Molecular Cell Biology in 2010. The CMOS biosensor technology used in Silicon BioDevices' products is based on his research, done in conjunction with Prof. Boser, Prof. Beatty and Prof. Harris. Octavian was also a Vodafone Fellow from 2004-2006 and holds two US patents with several more pending. Outside of IC design and biotechnology research, his interests include Austrian economics, philosophy and downhill skiing.
Gary Stroy is a pharmaceutical and medical device executive/entrepreneur. He was a senior manager at large pharmaceutical firms (GSK, Baxter, Syntex and Bayer), a founder of venture-backed medical device companies (Sicca Labs, LifeScan, Biotrack, ChemTrak, Aprise, Abaxis and LXN), an angel investor, venture/general partner with first-tier venture firms (Sequoia Capital, USVP, Delphi Ventures, MedVenture Associates and Walden International) and a board member at several drug and device firms (RxKinetix, Cutera, Avocet, NeurogesX, Coalescent Surgical, Accumetrics and Carbylan Biosurgery). Since 2005, Mr. Stroy has specialized in funding, restructuring or merging startup companies including Afmedica, Neuralieve, and IntelliDx.
Tayson Siegel has spent seven years as a medical device entrepreneur and a professional in the venture-backed startup community. After taking a strong interest in entrepreneurship as a student, he worked at SVB Capital and Vision Capital. He received his Bachelor’s degree in Mathematics and Economics from UC Berkeley and completed a certificate in the Management of Innovation and Technology at Berkeley’s Center for Entrepreneurship and Technology. In 2008, Tayson joined the other founders of Silicon BioDevices to help turn an exciting academic research project into a company with the potential for a major societal impact.
Dr. Daniel Wong has more than 30 years product R&D experience in the IVD field, delivering more than 25 commercial products. He was manager/senior manager in large firms (Bayer, Roche) and young firms (Abaxis, Amira Medical, later acquired by Roche). He has led development of assays, manufacturing processes, and systems for POC and self-monitoring of blood glucose use. He was also a working member of various management teams developing strategies for product innovation, strategic patenting, and innovation methods. He received his B.S. in Physics from the Illinois Institute of Technology and PhD in Biophysics from the University of Illinois at Urbana-Champaign. Daniel also holds 12 US patents with additional pending.
Duane Yamasaki was cofounder of Coagusense in 2008, where he led the Engineering and Operation of a Prothrombin Time Monitoring System for patients on oral anticoagulants. Duane brings extensive experience in developing, manufacturing and marketing medical devices to SBD, accrued over 20 years in the field with Ventus Medical, Alexza Pharmaceutical, TheraSense, Aclara BioScience and BioRad. Duane completed his BS in Mechanical Engineering from Cal State University, Sacramento in 1989 and has two US patents.
Board and Advisors
Thomas M. Loarie, Chairman, has participated in the healthcare industry for 34 years, bringing more than 20 medical devices to market worldwide. He has served as co-founder and Chairman of CardioProfile, Inc.; CEO and Chair man of KeraVision, Inc.; COO of Novacor, Inc.; and as President of American Heyer-Schulte (Division of American Hospital Supply, now Baxter, Inc.). He has served as Assistant Professor of Surgery, Creighton University Medical School; Chairman-elect, Board Member, and Executive Committee member, AdvaMed (the Advanced Medical Technology Association); and as a board member of the California Healthcare Institute. Mr. Loarie received his B.S.M.E. from the University of Notre Dame.
William McMillan, Board Member, was co-founder of Cepheid in 1996, creating and guiding its R&D organization. Previously, he was Program Manager for the development of a range of products, including a rapid, automated immunoassay analysis system for Syva Company, a subsidiary of Syntex Corporation. Prior to moving into industry, Mr. McMillan was a research public health microbiologist at the California State Department of Health, Microbial Diseases Laboratory. He graduated from San Jose State University with a BS in Chemistry and a MA in Microbiology. Currently, he is the Founder and CEO of Profusa.
Dr. Ronald M. Krauss, MD, Advisory Board Chairman, is Senior Scientist and Director of Atherosclerosis Research at Children's Hospital Oakland Research Institute, Adjunct Professor in the Department of Medicine at UCSF and in the Department of Nutritional Sciences at UC Berkeley, and Guest Senior Scientist in the Department of Genome Sciences of Lawrence Berkeley National Laboratory. He received his undergraduate and medical degrees from Harvard University with honors and served his internship and residency on the Harvard Medical Service of Boston City Hospital. He then joined the staff of the National Heart, Lung, and Blood Institute in Bethesda, Maryland, first as Clinical Associate and then as Senior Investigator in the Molecular Disease Branch. Dr. Krauss is a Fellow of the American Society of Nutrition and the American Heart Association (AHA). He a member of the U.S. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, founder and past Chair of the AHA Council on Nutrition, Physical Activity, and Metabolism, and a National Spokesperson for the AHA.
Paul L. Epner, MBA, MEd, Advisor, spent 31 years with Abbott Diagnostics (ADD) in the U.S., Japan and China. His Abbott career included the development and implementation of the initial business plan for POC diagnostics, directing the global market research function and directing an effort to standardize the data interface for ADD products. Paul is a member of CDC’s “Clinical Laboratory Integration into Healthcare Collaborative™” and serves on the Board of Directors of the Clinical Laboratory Management Association as well as the Global Health Committee of the Association for Public Health Laboratories.
Dr. Robert H. Christenson, PhD, DABCC, FACB, Advisor, is professor of pathology and medical and research technology at the University of Maryland School of Medicine and directs POC services and the clinical chemistry, toxicology, shock trauma and core laboratories at the UMD Medical Center. He chaired/sat on the editorial boards of Clinical Laboratory News, Clinical Chemistry, and the Journal of Clinical and Laboratory Analysis, and is associate editor at Clinical Biochemistry. He served on the boards of the NACB and the AACC, where he chaired the Evidence Based Medicine Committee, and he currently chairs the IFCC Committee on Evidence Based Laboratory Medicine. He has an active cardiac biomarker research program, holds 3 patents, and has published over 230 peer-reviewed manuscripts, 160 abstracts, 4 books, and 50 chapters /monographs.
Dr. W. Frank Peacock IV, MD, FACEP, Advisor, is the immediate past Chief Medical Officer of the Society of Cardiovascular Patient Care. Previously, Dr. Peacock served as Professor, Cleveland Clinic Lerner College of Medicine and Case Western Reserve University, Cleveland, Ohio, and was Vice Chair of Emergency Medicine Research at the Cleveland Clinic where he served also served as Director of Event Medicine (responsible for the Cleveland Browns, Cavaliers, and Indians’ Stadiums). He recently moved to become Professor of Emergency Medicine, Associate Chair, and Research Director for Emergency Medicine at the Baylor College of Medicine, in Houston, Texas. With over 300 publications on heart failure and acute coronary syndromes, Dr. Peacock is also the co-editor of the textbooks Cardiac Emergencies, Short Stay Management of Heart Failure, and Short Stay Management of Chest Pain and is or has been PI or co-PI for many high profile national and international clinical trials including PRONTO, ADHERE-EM, IMPACT, CHOPIN, CLUE, FASTTRACK, and TRUE-HF. Dr. Peacock received his MD from Wayne State University Medical School and completed his Emergency Medicine training at William Beaumont Hospital, Detroit, Michigan.